Apogee Therapeutics (APGE) Competitors $47.25 -3.76 (-7.37%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends APGE vs. ITCI, ROIV, ASND, LEGN, ELAN, CYTK, RNA, BPMC, VKTX, and NUVLShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Avidity Biosciences (RNA), Blueprint Medicines (BPMC), Viking Therapeutics (VKTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Legend Biotech Elanco Animal Health Cytokinetics Avidity Biosciences Blueprint Medicines Viking Therapeutics Nuvalent Apogee Therapeutics (NASDAQ:APGE) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Which has more risk & volatility, APGE or ITCI? Apogee Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Do analysts recommend APGE or ITCI? Apogee Therapeutics currently has a consensus target price of $78.50, suggesting a potential upside of 66.14%. Intra-Cellular Therapies has a consensus target price of $97.23, suggesting a potential upside of 16.56%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Apogee Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85 Do institutionals and insiders hold more shares of APGE or ITCI? 79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 36.1% of Apogee Therapeutics shares are held by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to APGE or ITCI? In the previous week, Apogee Therapeutics had 3 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 14 mentions for Apogee Therapeutics and 11 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 1.21 beat Apogee Therapeutics' score of -0.06 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Intra-Cellular Therapies 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is APGE or ITCI more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Apogee Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -21.81% -20.94% Intra-Cellular Therapies -14.07%-9.93%-8.38% Which has stronger earnings and valuation, APGE or ITCI? Apogee Therapeutics has higher earnings, but lower revenue than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$83.99M-$2.42-19.52Intra-Cellular Therapies$464.37M19.05-$139.67M-$0.87-95.88 Does the MarketBeat Community believe in APGE or ITCI? Intra-Cellular Therapies received 503 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 67.84% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformApogee TherapeuticsOutperform Votes18100.00% Underperform VotesNo VotesIntra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% SummaryApogee Therapeutics beats Intra-Cellular Therapies on 9 of the 17 factors compared between the two stocks. Ad Brownstone ResearchBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.13B$2.93B$5.15B$8.74BDividend YieldN/A1.88%5.18%4.08%P/E Ratio-19.5215.9865.5913.48Price / SalesN/A284.431,278.7587.67Price / CashN/A166.9239.7035.24Price / Book2.904.006.475.93Net Income-$83.99M-$42.42M$119.73M$225.73M7 Day Performance-22.69%-10.63%-5.13%-1.34%1 Month Performance-15.97%-5.81%-2.71%1.15%1 Year Performance158.20%24.19%31.08%24.02% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics2.3128 of 5 stars$47.25-7.4%$78.50+66.1%+181.1%$2.13BN/A-19.5291Analyst ForecastAnalyst RevisionNews CoverageITCIIntra-Cellular Therapies4.5093 of 5 stars$88.22-0.3%N/A+51.6%$9.35B$464.37M-101.40560Insider SellingPositive NewsROIVRoivant Sciences3.4226 of 5 stars$11.95+2.7%N/A+24.2%$8.84B$124.79M2.12860Analyst ForecastNews CoverageASNDAscendis Pharma A/S3.06 of 5 stars$126.03-1.3%N/A+35.3%$7.64B$288.08M-13.54640Analyst DowngradeShort Interest ↑News CoverageGap DownLEGNLegend Biotech1.8575 of 5 stars$39.35-2.1%N/A-39.9%$7.17B$285.14M-41.421,800Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageELANElanco Animal Health3.526 of 5 stars$14.19+0.5%N/A+21.5%$7.01B$4.42B35.489,300Short Interest ↑CYTKCytokinetics4.0709 of 5 stars$55.96-0.4%N/A+58.5%$6.60B$7.53M-10.40250Insider SellingRNAAvidity Biosciences2.5072 of 5 stars$52.50+12.3%N/A+611.3%$6.26B$9.56M-18.23190Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeBPMCBlueprint Medicines3.0865 of 5 stars$96.88+0.3%N/A+41.6%$6.15B$249.38M-45.91640Analyst ForecastShort Interest ↑News CoverageVKTXViking Therapeutics4.5139 of 5 stars$55.06-9.1%N/A+370.8%$6.14BN/A-59.2020NUVLNuvalent3.1126 of 5 stars$90.34-0.7%N/A+49.7%$5.85BN/A-26.0340Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies ITCI Competitors ROIV Competitors ASND Competitors LEGN Competitors ELAN Competitors CYTK Competitors RNA Competitors BPMC Competitors VKTX Competitors NUVL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APGE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
